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LETTER TO EDITOR
Using T-cell repertoire profiles as predictor in a primary
mucosal melanoma
Dear Editor,
Primary mucosal melanoma is a rare subtype of
melanoma that carries poor prognosis. Traditional
treatment options of mucosal melanoma are surgery,
radiation, and chemotherapy; but the overall survival
remains low.1 Cytotoxic T-lymphocyte associated protein
4 (CLTA-4) and programmed cell death protein 1 (PD-1),
both inhibitory immune checkpoints commonly seen on
activated T cells, have been found to be promising targets
for treatment of advanced cancers.2 However, the efficacy
and response to immunotherapy in mucosal melanoma
remains unknown. Herein, we report a case involving a
patient, who was a 70-year-old male and referred to Taipei
Medical University Hospital with confirmed diagnosis of
mucosa melanoma over hard plate of mouth. The patient
was admitted and subjected to anti-PD-1 immunotherapy
(pembrolizumab 200mg every 3 weeks) (Figure 1A). Serial
imaging of primary malignant melanoma of the hard
palate showed that the tumor size gradually decreased
after treatment with pembrolizumab, suggesting par-
tial response/stable disease secondary to continuous
immunotherapy (Figure 1B). However, after seventh cycle
of treatment, magnetic resonance imaging (MRI) revealed
enlarged previous known metastatic lesions and new
tumor nodules in brain (Figure 1B). The patient received
stereotactic radiation therapy before treatment cycle
14 (Figure 1A). Although the primary metastatic brain
lesions were smaller and stationary after radiotherapy,
the following brain MRI displayed several hyperdensity
masses in the right frontal lobe with perifocal edema
and mild mass effect (Figure 1B). Subsequently, patient
suffered from infection and respiratory distress and died 2
months after 17th cycle of pembrolizumab therapy.
To monitor changes in patient’s circulating T-cell reper-
toire at each cycle of immunotherapy, high-throughput
TCRβ sequencing of peripheral blood mononuclear cells
(PBMCs), isolated from the patient’s peripheral blood, was
performed using a rapid amplification of 5′ complemen-
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tary DNA ends (5′RACE)-based approach and MiSeq sys-
tem as previously described.3,4 The blood samples were
collected from the patient prior to every intravenous injec-
tion of pembrolizumab (17 cycles total) over the course of
1 year (Figure 1A). We excluded two samples harvested at
treatment cycle 9 and 17 due to poor RNA quality. Thus, a
total of 15 TCR repertoire profiles were established. Longi-
tudinal profiling of TCRβ repertoire revealed a rise inTCRβ
diversity (Pielou’s evenness index) over the course of pem-
brolizumab therapy (Figure 1C).
To further investigate the temporal dynamics of TCRβ
repertoire in the patient during long-term immunother-
apy, the abundance of each TCRβ clonotype was tracked
throughout 15 time points. Longitudinal monitoring of
clonal abundance revealed a dominant TCRβ clonotype
(purple color) in T-cell repertoire at treatment cycle
1, while other clonotypes exhibited consistent varia-
tions throughout the course of treatment (Figure 2A).
Overall, rankings of TCRβ repertoire clonotypes did
not significantly fluctuate. Nevertheless, the proportion
of low-abundant clonotypes with frequency less than
0.1% (gray color) was significantly increased throughout
the treatment (Figure 2A). Within repertoire of TCRβ
clonotypes, some high abundance (>1%) clonotypes
significantly expanded during the treatment. In particular,
three TCRβ clonotypes, two of which were initially low-
abundant (<0.1%), simultaneously expanded more than
10-fold and became highly abundant (>1%) at cycle 11 and
then displayed almost consistent abundance through the
last time point of record (Figure 2B). In addition, dramatic
expansions of two low-abundant TCRβ clonotypes at cycle
7 (peak at eighth cycle) and 11 (peak at 12th cycle) were
observed (Figure 2B). Since T-cell-mediated immune
response is usually accompanied by the expansion of
polyclonal T cells to tumor antigens,5,6 we focused on
TCRβ clonotype clusters (groups) rather than single TCRβ
clonotype. A clustering method for temporal frequen-
cies of clonotypes was applied to detect low-abundant
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F IGURE 1 A, Time points of the course of treatment with pembrolizumab and sample collection. Blood samples from the patient were
harvested prior to every pembrolizumab injection. Two samples collected at treatment cycle 9 and 17 (labeled with red stars) were removed
due to poor RNA quality after nucleic acid extraction. B, Serial imaging of primary malignant melanoma (top panel) and magnetic resonance
imaging (MRI) ofmetastatic brain lesions (bottompanel) of the patient during the immunotherapywith pembrolizumab. C, Temporal dynamics
of TCRβ repertoire diversity (Pielou’s evenness index) in the patient throughout the treatment course
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F IGURE 2 A, Distribution of TCRβ
clonotypes of the patient during the
pembrolizumab immunotherapy. Only
clonotypes with frequency higher than 0.1% at
each time point were represented by different
colors. Each clonotype was illustrated by
identical color across samples. B, Temporal
dynamics of TCRβ clonotype abundance in
the patient throughout the treatment course.
Only abundant clonotypes with frequency
greater than 1% at any time point were
illustrated. C and D, Two groups of clustered
TCRβ clonotypes showing the clonal
expansion at time points between clinical
observations of new lesions in brain and
progression of brain metastasis. E and F, Two
groups of clustered TCRβ clonotypes showing
the clonal expansion at time points after
radiation therapy. Arrows indicated the time
points of dominant clonal expansion (red)
and the clinical records (black) of the patient.
Only abundant clonotypes with frequencies
reaching top 1% at any time point at least once
were included for clustering analysis
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clonotypes that possessed similar clonal dynamics.7 We
herein selected significantly expended TCRβ clonotypes
with frequencies reaching top 1% at any time point at
least once for the clustering analysis and identified four
major groups of clonotypes showing divergent temporal
dynamic patterns accordingly. Notably, obvious expan-
sions followed by contractions of two groups of TCRβ
clonotypes were detected at treatment cycle 11 (Figure 2C)
and 12 (Figure 2D), the time points between new lesion
being identified (before treatment cycle 8) and observasion
of metastatic brain tumor progression (after treatment
cycle 13). Such findings suggested a correlation between
partial clonal expansion of TCR repertoire and progres-
sion of metastatic tumor lesions, that is, the response of
parts of T-cell clonotypes to the tumor growth, although
the overall repertoire diversity was increasing during
anti-PD-1 treatment. Another two groups of TCRβ clono-
types represented significant polyclonal expansion and
contraction with peak at treatment cycle 14 (Figure 2E)
and 15 (Figure 2F), both of which coincide in time with
postradiation therapy. Such findings showed a strong
interventional effect of local radiotherapy on peripheral
T-cell repertoire status of the patient.
Currently, not much is known about the changes of
immune repertoire following long-term treatment of PD-
1 inhibitor for this type of rare cancer, especially in Asian
population. To our knowledge, this is the first report that
describes T-cell repertoire dynamics in a patient diagnosed
with mucosal melanoma while receiving long-term treat-
ment of pembrolizumab. In this study, we carefully mon-
itored TCRβ profiles at 15 time points of 17-cycle pem-
brolizumab treatment.Overall, an increased trend of reper-
toire diversity throughout thewhole treatment courseswas
observed. Such finding is consistent with previous report,
which showed a decreased clonality scores of peripheral
bloodCD8+ T-cell repertoire after anti-PD-1 treatment plus
brain stereotactic radiation in a melanoma patient.8 In
addition, clustering of TCRβ clonotypes in this study pro-
vided a better resolution to detect low-abundant clono-
types that possessed similar clonal dynamics as high-
abundant clonotypes. We observed polyclonal expansions
within T-cell repertoire at multiple time points during
pembrolizumab treatment. Most of clustered TCRβ clono-
types were initially undetected or low abundant during
the early stage of the immunotherapy. These clonotypes
showed a clear pattern of clonal expansion followed by
contraction at two later time periods where twomajor clin-
ical events, tumor progression and radiation treatment,
could be observed. Our results indicated that the expan-
sion of low-frequent TCRβ clonotypes within whole TCR
repertoire pool might correlate with clinical outcomes of
the patient. Consistent with this, association between fluc-
tuation of TCR clonotypes and clinical outcomes during
the period of cancer immune therapy has been reported
before.8-10 The clonal expansion of TCR clonotypes might
be attributed to antitumoral T-cell responses to neoanti-
gens derived from tumor cells during cancer progression
and treatment.11,12 However, more samples and animal
models will be helpful to identify pharmacological mech-
anisms of long-term combinational immunotherapy in T-
cell repertoire of patients with such a rare melanoma dis-
ease.
In conclusion, our study revealed an increase of whole
TCRβ repertoire diversity over the anti-PD-1 immunother-
apy and a large amount of low-abundant TCRβ clonotypes
expanded in the periphery of the patient during disease
progression and radiation therapy intervention. Thus,
successful identification of the TCR clone expansion,
repertoire diversity as well as clustering of low frequency
clonotypes might be a useful tool to predict responses of
immune checkpoint blockade therapy.
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